Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Advances review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://williaml753ikk3.wikicommunications.com/user